SH2 domain binding inhibitors


Ontology type: sgo:Patent     


Patent Info

DATE

2008-09-16T00:00

AUTHORS

BURKE JR TERRENCE R , WEI CHANG-QING , SHI ZHEN-DAN , GAO YANG

ABSTRACT

Disclosed are compounds for SH2 domain binding inhibition, for example, a compound of formula (I), wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R6 is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. The conformationally compounds provide enhanced binding affinity with SH2 domain protein. Also disclosed are a pharmaceutical compositions and a method for inhibiting an SH2 domain from binding with a phosphoprotein. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "BURKE JR TERRENCE R", 
        "type": "Person"
      }, 
      {
        "name": "WEI CHANG-QING", 
        "type": "Person"
      }, 
      {
        "name": "SHI ZHEN-DAN", 
        "type": "Person"
      }, 
      {
        "name": "GAO YANG", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/385602a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034217411", 
          "https://doi.org/10.1038/385602a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nsb0796-586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003931922", 
          "https://doi.org/10.1038/nsb0796-586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/358646a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021461565", 
          "https://doi.org/10.1038/358646a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/377032a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001223281", 
          "https://doi.org/10.1038/377032a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1201053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002043356", 
          "https://doi.org/10.1038/sj.onc.1201053"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-09-16T00:00", 
    "description": "

Disclosed are compounds for SH2 domain binding inhibition, for example, a compound of formula (I), wherein R1 is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3 is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R3 may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R6 is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. The conformationally compounds provide enhanced binding affinity with SH2 domain protein. Also disclosed are a pharmaceutical compositions and a method for inhibiting an SH2 domain from binding with a phosphoprotein.

", "endDate": "2022-05-23", "id": "sg:patent.US-7425537-B2", "name": "SH2 domain binding inhibitors", "sameAs": [ "https://app.dimensions.ai/details/patent/US-7425537-B2" ], "sdDataset": "patents", "sdDatePublished": "2022-10-01T07:03", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/patent/patent_20.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-7425537-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-7425537-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-7425537-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-7425537-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

56 TRIPLES      14 PREDICATES      20 URIs      9 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-7425537-B2 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N46d9651d909e4d2594df1358c9927b31
4 schema:citation sg:pub.10.1038/358646a0
5 sg:pub.10.1038/377032a0
6 sg:pub.10.1038/385602a0
7 sg:pub.10.1038/nsb0796-586
8 sg:pub.10.1038/sj.onc.1201053
9 schema:datePublished 2008-09-16T00:00
10 schema:description <p num="p-0001">Disclosed are compounds for SH2 domain binding inhibition, for example, a compound of formula (I), wherein R<sub>1 </sub>is a lipophile; R<sub>2</sub>, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R<sub>3 </sub>is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R<sub>3 </sub>may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R<sub>6 </sub>is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. The conformationally compounds provide enhanced binding affinity with SH2 domain protein. Also disclosed are a pharmaceutical compositions and a method for inhibiting an SH2 domain from binding with a phosphoprotein.</p>
11 schema:endDate 2022-05-23
12 schema:name SH2 domain binding inhibitors
13 schema:sameAs https://app.dimensions.ai/details/patent/US-7425537-B2
14 schema:sdDatePublished 2022-10-01T07:03
15 schema:sdLicense https://scigraph.springernature.com/explorer/license/
16 schema:sdPublisher Nf634baf70b924630a20aef04200f5f61
17 sgo:license sg:explorer/license/
18 sgo:sdDataset patents
19 rdf:type sgo:Patent
20 N006d6dc64f784c1b94d813af9dcf78ec schema:name SHI ZHEN-DAN
21 rdf:type schema:Person
22 N0e678fe904d8401d877b3a4f5ec8ae1b schema:name WEI CHANG-QING
23 rdf:type schema:Person
24 N4161c76ca8c94da0b86390cd3cba86fc schema:name BURKE JR TERRENCE R
25 rdf:type schema:Person
26 N46d9651d909e4d2594df1358c9927b31 rdf:first N4161c76ca8c94da0b86390cd3cba86fc
27 rdf:rest Nea4126fd41b0479eac59e4553c7579ba
28 N49ca06379fe7498bbfe903ea01e5296b rdf:first N006d6dc64f784c1b94d813af9dcf78ec
29 rdf:rest Nb44809bcd5164abebaba6d79b8194f70
30 Nb44809bcd5164abebaba6d79b8194f70 rdf:first Nf9b7365dbbe24ae6a92c1b7cbb40c3b3
31 rdf:rest rdf:nil
32 Nea4126fd41b0479eac59e4553c7579ba rdf:first N0e678fe904d8401d877b3a4f5ec8ae1b
33 rdf:rest N49ca06379fe7498bbfe903ea01e5296b
34 Nf634baf70b924630a20aef04200f5f61 schema:name Springer Nature - SN SciGraph project
35 rdf:type schema:Organization
36 Nf9b7365dbbe24ae6a92c1b7cbb40c3b3 schema:name GAO YANG
37 rdf:type schema:Person
38 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
39 rdf:type schema:DefinedTerm
40 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
41 rdf:type schema:DefinedTerm
42 sg:pub.10.1038/358646a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021461565
43 https://doi.org/10.1038/358646a0
44 rdf:type schema:CreativeWork
45 sg:pub.10.1038/377032a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001223281
46 https://doi.org/10.1038/377032a0
47 rdf:type schema:CreativeWork
48 sg:pub.10.1038/385602a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034217411
49 https://doi.org/10.1038/385602a0
50 rdf:type schema:CreativeWork
51 sg:pub.10.1038/nsb0796-586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003931922
52 https://doi.org/10.1038/nsb0796-586
53 rdf:type schema:CreativeWork
54 sg:pub.10.1038/sj.onc.1201053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002043356
55 https://doi.org/10.1038/sj.onc.1201053
56 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...